The COPD therapy market is a crowded space in which several LAMAs (e.g., Boehringer Ingelheim’s Spiriva, AstraZeneca’s Tudorza), LABA/ICSFDCs (e.g., GlaxoSmithKline’s Advair and Breo,…
The COPD therapy market is a crowded space in which several LAMAs (e.g., Boehringer Ingelheim’s Spiriva, AstraZeneca’s Tudorza), LABA/ICSFDCs (e.g., GlaxoSmithKline’s Advair and Breo,…
MARKET OUTLOOK Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are beginning to gain traction in the COPD market, and both LAMAs and …
Current market-leading therapies in the U.S. COPD market will face challenges from emerging drugs, especially generic versions of Spiriva, Symbicort, and Advair. Surveyed physicians often report …
Most patients with chronic obstructive pulmonary disease (COPD) in the five European countries under study receive treatment shortly after diagnosis. The progressive nature of the disease results…
The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand and is expected to grow from approximately $15…
The COPD treatment algorithm continues to evolve, with changing recommendations on the use of ICS s, LABA / ICS FDC s, and LABA / LAMA FDC s. This study reveals which therapies are prescribed first…
The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand and is expected to grow from approximately $15…
The U.S. therapy market for chronic obstructive pulmonary disease (COPD) is becoming increasingly crowded. As more therapies with similar clinical profiles launch and the threat of generic versions…
The chronic obstructive pulmonary disease (COPD) market is becoming increasingly crowded, but significant unmet need remains due to the lack of a disease-modifying therapy. In recent years, several…
Last Updated 14 December 2015 The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand. The prevalence…
For the estimated 9 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, there are multiple prescription therapies that are available for treating the…
Increasing formulary competition and decreasing product differentiation have led to an aggressive pricing war in the U.S. asthma and chronic obstructive pulmonary disorder (COPD) markets. As…
A Survey of Pulmonologists and Managed Care Organization Pharmacy and Medical Directors The U.S. market for chronic obstructive pulmonary disease (COPD) therapies consists entirely of symptomatic…
Chronic obstructive pulmonary disease (COPD) is a progressive lung disorder and the third-leading cause of death in the United States. No currently available therapy treats the underlying cause of…